Background. We describe a heart transplant patient with painful periostitis and exostoses who was receiving long-term therapy with voriconazole, which is a fluoride-containing medication. Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels.
voriconazole, which she continued to receive thereafter. Six months after receiving the transplant, she experienced painful bony growths on her fingers, wrists, elbows, legs, and feet.
Her physical examination revealed bony prominences on her elbows, right forearm, fingers, and left foot. Skeletal radiographs showed innumerable areas of periosteal ossification arising from the cortical surfaces of multiple bones in the axial and appendicular skeleton (Figure 1 ). Laboratory findings identified high bone turnover markers and plasma and bone fluoride levels ( Table 1) . The patient denied all sources of high fluoride intake, including fluoride-containing medications, excessive black tea consumption, and swallowing toothpaste. A transiliac crest bone biopsy showed thickened and increased osteoid-covered surfaces with poorly resolved tetracycline labels consistent with osteomalacia ( Figure 2 ). The bone histomorphometric measures revealed increased osteoid volume (Z-score 5 4.1) and surface (Z-score 5 5.2), reduced mineral apposition rate (Z-score 5 21.1), and increased mineralization lag time (Z-score 5 5.7). Because of the clinical findings, voriconazole was replaced with itraconazole, and within 1 month, the patient's pain improved. Two months after discontinuation of voriconazole, her alkaline phosphatase level had decreased by 50%, and at 3 months, her plasma fluoride level had decreased to 13.2 lmol/L.
Voriconazole is a triazole antifungal agent approved for clinical use by the US Food and Drug Administration in May 2002. It works primarily by inhibiting cytochrome P450 14a-demethylase, which is an enzyme in the sterol biosynthesis pathway. Voriconazole contains 3 fluoride atoms (16.3% by weight) and is one of several medications that contain fluoride [2] [3] [4] . Although voriconazole has not been previously associated with fluoride toxicity, it was the only source of excessive fluoride exposure identified in this patient. To determine whether voriconazole may be a cause of fluoride excess, we evaluated plasma fluoride levels in adult patients after transplantation who were receiving voriconazole for at least 6 months, compared with levels in transplant recipients who were not taking voriconazole.
METHODS
After the study was approved by the Mayo Clinic Institutional Review, 20 post-transplant patients were recruited by 3 of the investigators (R.A.W., R.R.R., and P.J.D.) from the Mayo Clinic Rochester William J. von Liebig Transplant Center during the period October 2009-April 2010 and consented to adding a plasma fluoride test to their usual laboratory testing, which routinely included the measurement of serum creatinine with an estimated glomerular filtration rate (eGFR); calcineurin inhibitor and voriconazole levels, when applicable; and alkaline phosphatase level. The majority of laboratory testing (80%) was done when the patient was in a fasting state. Inclusion criteria for 10 voriconazole group subjects required receipt of voriconazole at a dosage of 200 mg twice daily by mouth for at least 6 months. A 400-mg daily dose of voriconazole contains 65 mg of fluoride. Also, 5 voriconazole group subjects were recruited on the basis of a serum creatinine level of >1.4 mg/dL on their most recent measurement prior to recruitment, whereas the other 5 voriconazole group subjects had serum creatinine levels ,1.4 mg/dL on their most recent measure. A cut-off serum creatinine level of 1.4 mg/dL was arbitrarily chosen to evaluate whether renal insufficiency predisposed voriconazole group subjects to fluoride accumulation [5] . The control group inclusion criteria included serum creatinine level >1.4 mg/dL on the most recent measurement prior to recruitment, which theoretically put the subject at higher risk for fluoride accumulation. In addition, control subjects were to have never taken voriconazole. Patients were excluded from both groups if they were unable to give study consent, were ,18 years of age, were pregnant, or used a fluorinated pharmaceutical other than voriconazole in the study group [2] [3] [4] .
Voriconazole tablets provided by our pharmacy were dissolved in normal saline and evaluated for fluoride content. Fluoride in plasma and the voriconazole tablets were quantified using a La Motte pH PLUS Direct pH/mV/ISE/Temp meter equipped with a fluoride-specific electrode (Orion Research). The fluoride electrode consists of a single-crystal lanthanum fluoride membrane and an internal reference bonded into an epoxy body. The crystal is an ionic conductor in which only fluoride ions are mobile. A TISAB reagent (1% Acetic Acid, 6% Sodium Chloride, 8% Sodium Acetate, and ,1% 1,2-Cyclohexane Diaminetetraacetic Acid in water) was used to buffer the sample prior to ion selective electrode analysis. Experience in the Mayo Clinical Laboratory associated with evaluation of patients exposed to fluoride from common sources, including the diet, beverages, drinking water, and the normal use of fluoride toothpastes, indicates that plasma fluoride is consistently within the range of 1-4 lmol/L. Serum creatinine was determined by an enzymatic colorimetric assay calibrated to an isotope dilution mass spectrometry (IDMS)-traceable method. The e-GFR was calculated from serum creatinine data using the IDMS- The iliac crest bone specimen from the index case patient was ashed at 600°C overnight and pulverized into a finely divided white powder. The fluoride concentration in the bone ash was determined in triplicate using the ion-specific electrode (Orion Research, Model 9409) and a miniature calomel reference electrode both coupled to a potentiometer (Orion Research, Model 720A) after overnight hexamethyldisiloxane-facilitated diffusion [6, 7] . This method quantitatively extracts fluoride, even from insoluble minerals, including fluorapatite. Three bracketing fluoride standards were diffused in triplicate along with the bone samples.
Numerical data were described by mean, standard deviation, and range, and the groups were compared using the Student's t test with unequal variances. Categorical data were described by counts and percentages, and groups were compared using Fisher's exact test.
RESULTS
Voriconazole group subjects were significantly younger (P 5 .003) and included more women (Tables 2 and 3) , compared with the control group subjects. There were more lung transplant recipients in the voriconazole group, reflecting the routine use of antifungal prophylaxis in these patients. Five patients in the control group were receiving an alternative antifungal agent (itraconazole), which does not contain fluoride.
All patients receiving voriconazole had elevated plasma fluoride levels, compared with no patients in the control group (P , .001) ( Tables 2 and 3 ). Alkaline phosphatase levels were also significantly higher in the voriconazole group (P 5 .003). Age was a significant predictor of plasma fluoride levels in univariate analysis (P 5 .047) but not when included in a regression model with voriconazole (P 5 .534). Creatinine level was not a significant predictor of fluoride levels in univariate analysis (P 5 .376) or when included in a regression model with voriconazole (P 5 .889). The eGFR was also not predictive of plasma fluoride levels in univariate analysis (P 5 .372) or when included in a regression model with voriconazole (P 5 .653). Calcineurin inhibitor levels were marginally predictive of plasma fluoride levels (cyclosporine, P 5 .110; tacrolimus, P 5 .065, fit jointly). Calcineurin inhibitor doses were potentially predictive of plasma fluoride levels (cyclosporine, P 5 .196; tacrolimus, P 5 .017, fit jointly). Nonetheless, fluoride levels remained significantly higher in the voriconazole group after adjusting for cyclosporine and tacrolimus blood levels (P , .001) and doses (P , .001). Considering only the patients who received voriconazole, the correlation between serum voriconazole levels and plasma fluoride levels was not statistically significant (rho 5 2.27; P 5 .481). The voriconazole tablets from our pharmacy contained no soluble fluoride ion.
Periositis with significant pain symptoms was identified in 5 voriconazole group subjects (50%) and included multiple exostoses in 2 subjects (20%) ( Table 2 ). Formal referral of the 2 study subjects with exostoses to transplant endocrinology allowed more-detailed investigation of these patients (Table 1) . Bone scans for both subjects demonstrated multiple scattered foci of radiotracer uptake in the ribs and appendicular skeleton. Their laboratory evaluation revealed elevated bone turnover and plasma fluoride levels. Both patients denied all potential sources of excessive fluoride, and fluoride water testing from primary residence was within or below the recommended range for caries control (0.7-1.2 mg/L). Voriconazole therapy was discontinued in both patients, and within 2 months, improvement in bone pain and reduction of alkaline phosphatase levels was observed. Fluoride levels were re-measured after 2 months in 1 of the subjects and decreased from 27 lmol/L to 7.5 lmol/L. Similarly, in 2 subjects with pain and periostitis without exostoses, voriconazole treatment was also discontinued, and this led to prompt improvement in pain. Normalization of alkaline phosphatase level and a decrease in the plasma fluoride level from 15.9 lmol/L to 6.3 lmol/L after 2 months was found in 1 of the subjects with follow-up measurements. The third subject with periostitis without exostoses in whom voriconazole treatment was discontinued has not been seen in follow-up.
DISCUSSION
We have identified a group of transplant patients with periostitis, including the growth of painful palpable exostoses, who were receiving long-term voriconazole therapy. Evaluation identified fluoride excess as the likely cause in subjects in whom a more detailed evaluation was obtained. In addition, discontinuation of voriconazole treatment in subjects with periostitis improved pain symptoms and reduced alkaline phosphatase and plasma fluoride levels. Evaluation of transplant patients taking voriconazole for at least 6 months demonstrated that plasma fluoride levels were uniformly elevated and significantly higher than levels in transplant patients who were not taking voriconazole.
Fluoride induces bone formation by stimulating osteoblasts. Elevations of serum alkaline phosphatase, which is a marker of bone formation, reflect this activity. Despite the impressive increases in bone mineral density seen with fluoride, bone quality is impaired at nonvertebral sites in some patients who receive long-term treatment with pharmacologic dosages [8, 9] . . Furthermore, bone histomorphometric analysis has identified changes that are consistent with osteomalacia, including prolonged mineralization lag time and increased osteoid thickness [8] . The adverse skeletal effects of fluoride have been reported in patients who receive long-term treatment and have mean plasma fluoride levels of approximately 8 lmol/L [9, 10] . Long-term fluoride intoxication has several features that can be seen on skeletal imaging, including osteosclerosis, hyperostotic periostitis, osteoporosis, ligamentous calcification, and periarticular changes, such as invasive osteophytes and joint arthrosis [1, 11] . The natural history of exostosis in fluorosis has been described as an initial period of hyperostosis in which boney lesions develop in fingers, forearms, and femurs. After initial growth over a period of 3-5 months, an osteoclastic stage ensues. However, residual periosteal bone growths persist, leading to the distinct name of this disorder, dating from descriptions given in 1952 of ''periostitis deformans'' [12] .
The initial description of fluoride-related periostitis in 1952 resulted from the consumption of Spanish wines that used fluorine as a preservative [12] . Skeletal fluorosis is endemic in some parts of the world and is predominantly related to large amounts of fluoride in the drinking water, environmental sources, and food sources, including tea [13] [14] [15] [16] . Other less common sources of fluoride include toothpaste, medications, and fluoride supplements [17] .
Fluoride toxicity has not been previously reported with voriconazole. There are several possible explanations for fluoride excess associated with long-term voriconazole use, despite the lack of measurable fluoride in voriconazole tablets. Fluorine is organically bound in voriconazole, and although not directly measured, it is not reported to immediately increase ionized fluoride levels [18] . However, 5% of voriconazole is metabolized to free fluoride [19] , and reports on the metabolism of voriconazole do not account for 30% of its excreted products [20] . It is possible that voriconazole, via hepatic oxidative metabolism, results in unbound fluoride metabolites that cause variably elevated fluoride levels after extended use in predisposed patients via pharmacogenomic variations in drug metabolism. Findings reported here bear similarity to earlier observations that associated fluoride toxicity to isoflurane administration [21, 22] , which has since been shown to be related to cytochrome P4502E1 (CYP2E1) genetic variance among patients by Wandel [23] . We hypothesize a similar mechanism is involved in these findings. A second possibility is that renal insufficiency predisposes individuals to fluoride accumulation, because its renal clearance is directly related to glomerular filtration rate [5] . Increased risk of adverse skeletal effects of fluoride has also been associated with renal insufficiency [24, 25] . However, plasma fluoride levels were elevated in all voriconazole group patients, and renal function was not predictive of fluoride levels.
The development of periostitis has been described in 5 lung transplant patients receiving long-term voriconazole [26] . Alkaline phosphatase levels were elevated, and imaging revealed diffuse periostitis. Improvement of symptoms occurred after voriconazole discontinuation. Repeat bone scans after voriconazole treatment was stopped in 2 of the lung transplant recipients resulted in marked improvement of the diffuse foci of increased uptake that had previously been identified. However, fluoride measurements were not obtained, and the underlying etiology for the periostitis was not identified. More recently, an additional 5 lung transplant recipients with periostitis who were receiving voriconazole were reported, but the description was primarily limited to radiographic features, and fluoride levels were not measured [27] .
There are several study limitations that should be considered when interpreting our results. First, the number of subjects was small. Also, the effect of voriconazole on plasma fluoride levels in subjects without transplants and in subjects who had received voriconazole for ,6 months were not evaluated. By design, the control group had worse renal function than did the voriconazole group, which could predispose the control group to fluoride accumulation. The voriconazole group was also younger and had one more female than the control group. However, age, renal function, and sex were not predictive of plasma fluoride levels in the multivariate analysis. Also, we did not perform a detailed investigation of bone metabolism, such as an assessment of vitamin D and PTH measurement or routine skeletal imaging, in the majority of subjects. Most subjects also did not have evaluation of home fluoride water levels. Although a detailed assessment of fluoride containing medications was performed, we did not perform a standardized dietary fluoride evaluation. Finally, 24-h urinary fluoride levels were not measured, although they are typically proportional to plasma concentrations and are influenced by similar variables, such as the amount of fluoride ingestion, the rate and extent of fluoride absorption, and the rate of skeletal and renal clearance of fluoride [5] .
Voriconazole, a fluoride-containing medication, is associated with the development of painful periostitis and exostoses due to fluoride excess in post-transplant patients who receive longterm treatment with this medication. Furthermore, plasma fluoride levels are commonly elevated in transplant patients who take voriconazole for at least 6 months and, in some cases, are markedly high. The improvement of periostitis after voriconazole discontinuation in lung transplant recipients [26] , several voriconazole group subjects from this study, and our index case patient also suggests causality. Furthermore, plasma fluoride levels decreased shortly after voriconazole treatment was stopped in patients in whom it was measured. Clinical recognition of the insidious features of fluoride excess is important in patients taking voriconazole, because prompt improvement in symptoms may be seen with its discontinuation. Further investigation will be necessary to identify factors that predispose individuals to significant fluoride excess and periostitis when taking voriconazole, particularly given its benefit in treating invasive Aspergillus and other mycelial infections.
